Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 4
2017 4
2018 1
2019 1
2020 1
2021 1
2022 3
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Effects of BNP and Sacubitrilat/Valsartan on Atrial Functional Reserve and Arrhythmogenesis in Human Myocardium.
Primessnig U, Deißler PM, Wakula P, Tran KL, Hohendanner F, von Lewinski D, Blaschke F, Knosalla C, Falk V, Pieske B, Grubitzsch H, Heinzel FR. Primessnig U, et al. Front Cardiovasc Med. 2022 Jul 5;9:859014. doi: 10.3389/fcvm.2022.859014. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35865376 Free PMC article.
BACKGROUND: Although the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan started a new era in heart failure (HF) treatment, less is known about the tissue-level effects of the drug on the atrial myocardial functional reserve and arrhythmogenesis. ...I …
BACKGROUND: Although the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan started a new era in heart failure (HF …
Pharmacokinetics and pharmacodynamics of sacubitril/valsartan in peritoneal dialysis patients.
He Y, Jin Y, Xue H, Liu R, Zhang M, Liao R, Chen M, Zhou X, He X, Qin M, Li K, Zou H, Gan Y, Wang Z, Zheng L, Zhong H, Fu P. He Y, et al. Nephrol Dial Transplant. 2023 Jul 31;38(8):1880-1889. doi: 10.1093/ndt/gfad038. Nephrol Dial Transplant. 2023. PMID: 36787894
METHODS: This was an open-label and cross-sectional study investigating PD patients diagnosed with hypertension or New York Heart Association Class II-IV HF. The concentrations of valsartan, sacubitril and sacubitrilat (LBQ657) were measured by ultra-performance liq …
METHODS: This was an open-label and cross-sectional study investigating PD patients diagnosed with hypertension or New York Heart Associatio …
Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.
Ayalasomayajula S, Langenickel T, Pal P, Boggarapu S, Sunkara G. Ayalasomayajula S, et al. Clin Pharmacokinet. 2017 Dec;56(12):1461-1478. doi: 10.1007/s40262-017-0543-3. Clin Pharmacokinet. 2017. PMID: 28417439 Review.
Absorption of sacubitril/valsartan and conversion of sacubitril (prodrug) to sacubitrilat (neprilysin inhibitor) was rapid with maximum plasma concentrations of sacubitril, sacubitrilat, and valsartan (angiotensin receptor blocker) reaching within 0.5, …
Absorption of sacubitril/valsartan and conversion of sacubitril (prodrug) to sacubitrilat (neprilysin inhibitor) was rapid wit …
Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats.
Li Q, Fang Y, Peng DW, Li LA, Deng CY, Yang H, Kuang SJ, Li QQ, Zhang MZ, Zeng P, Zhang QH, Liu Y, Deng H, Wei W, Xue YM, Wu SL, Rao F. Li Q, et al. Eur J Pharmacol. 2023 Aug 5;952:175754. doi: 10.1016/j.ejphar.2023.175754. Epub 2023 May 12. Eur J Pharmacol. 2023. PMID: 37182595
AIM: Sacubitril/valsartan (Sac/Val, LCZ696), the world's first angiotensin receptor-neprilysin inhibitor (ARNi), has been widely used in the treatment of heart failure. ...While the protein expression of angiotensin-converting enzyme-1 (ACE-1), angiotensin, angiotensin II …
AIM: Sacubitril/valsartan (Sac/Val, LCZ696), the world's first angiotensin receptor-neprilysin inhibitor (ARNi), has been widely used …
Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril/valsartan in heart failure.
Litwin SE, East CA. Litwin SE, et al. Front Cardiovasc Med. 2022 Dec 22;9:1058998. doi: 10.3389/fcvm.2022.1058998. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36620638 Free PMC article. Review.
Of the various medical therapies for heart failure (HF), sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor that combines sacubitril, a pro-drug that is further metabolized to the neprilysin inhibitor sacubitrilat, and the angiotensin …
Of the various medical therapies for heart failure (HF), sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inh …
Pharmacokinetics and safety of sacubitril/valsartan (LCZ696) in patients with mild and moderate hepatic impairment.
Kulmatycki KM, Langenickel T, Ng WH, Pal P, Zhou W, Lin TH, Rajman I, Chandra P, Sunkara G. Kulmatycki KM, et al. Int J Clin Pharmacol Ther. 2017 Sep;55(9):728-739. doi: 10.5414/CP202988. Int J Clin Pharmacol Ther. 2017. PMID: 28737127
Blood samples were collected at pre-determined time points to assess pharmacokinetics of sacubitril, sacubitrilat, and valsartan. Subjects with severe hepatic impairment were excluded as valsartan exposure is expected to be substantially increased in these pa …
Blood samples were collected at pre-determined time points to assess pharmacokinetics of sacubitril, sacubitrilat, and valsartan …
Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.
Ayalasomayajula S, Langenickel T, Pal P, Boggarapu S, Sunkara G. Ayalasomayajula S, et al. Clin Pharmacokinet. 2018 Jan;57(1):105-123. doi: 10.1007/s40262-017-0558-9. Clin Pharmacokinet. 2018. PMID: 28527109
Absorption of sacubitril/valsartan and conversion of sacubitril (prodrug) to sacubitrilat (neprilysin inhibitor) was rapid with maximum plasma concentrations of sacubitril, sacubitrilat, and valsartan (angiotensin receptor blocker) reaching within 0.5, …
Absorption of sacubitril/valsartan and conversion of sacubitril (prodrug) to sacubitrilat (neprilysin inhibitor) was rapid wit …
From ARB to ARNI in Cardiovascular Control.
Uijl E, Roksnoer LC, Hoorn EJ, Danser AH. Uijl E, et al. Curr Hypertens Rep. 2016 Dec;18(12):86. doi: 10.1007/s11906-016-0694-x. Curr Hypertens Rep. 2016. PMID: 27837397 Free PMC article. Review.
Simultaneous angiotensin II type 1 receptor blockade and neprilysin inhibition ('ARNI') with valsartan/sacubitril (LCZ696) might potentiate the beneficial effects of renin-angiotensin-aldosterone inhibition by reinforcing its endogenous counterbalance, the natriuretic pept …
Simultaneous angiotensin II type 1 receptor blockade and neprilysin inhibition ('ARNI') with valsartan/sacubitril (LCZ696) might pote …
Development and validation of a sensitive and simple LC-MS/MS method for simultaneous quantitation of valsartan, sacubitril and sacubitrilat in pediatric population.
Yang Q, Cao P, Lv Y, Peng H, Zhai X. Yang Q, et al. J Pharm Biomed Anal. 2024 Jan 20;238:115829. doi: 10.1016/j.jpba.2023.115829. Epub 2023 Oct 30. J Pharm Biomed Anal. 2024. PMID: 37948774
Trough concentration of the three substances to be measured were: valsartan (11.3-938.0 ng/mL), sacubitril (0.5-395.5 ng/mL) and sacubitrilat (522.1-4890.0 ng/mL). Overall, this is the first study to simultaneously determined the plasma valsartan, sacubitril …
Trough concentration of the three substances to be measured were: valsartan (11.3-938.0 ng/mL), sacubitril (0.5-395.5 ng/mL) and s …
Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects.
Akahori M, Ayalasomayajula S, Langenickel T, Pal P, Zhou W, Sunkara G. Akahori M, et al. Eur J Drug Metab Pharmacokinet. 2017 Jun;42(3):407-416. doi: 10.1007/s13318-016-0354-1. Eur J Drug Metab Pharmacokinet. 2017. PMID: 27324506 Clinical Trial.
Plasma and urine samples from 40 subjects receiving LCZ696 were collected to assess pharmacokinetics of LCZ696 analytes (sacubitril, sacubitrilat, and valsartan). RESULTS: Following single oral dose administration of LCZ696, sacubitril and valsartan rapidly a …
Plasma and urine samples from 40 subjects receiving LCZ696 were collected to assess pharmacokinetics of LCZ696 analytes (sacubitril, sacu …
18 results